Literature DB >> 30661024

Secondhand smoke alters arachidonic acid metabolism and inflammation in infants and children with cystic fibrosis.

Benjamin T Kopp1,2, Rohan Thompson1, Jeeho Kim2, Robert Konstan2, Alejandro Diaz3, Bennett Smith3, Chandra Shrestha2, Lynette K Rogers4, Don Hayes1, Dmitry Tumin5, Frederick W Woodley6, Octavio Ramilo3, Don B Sanders7, Judith A Groner8, Asuncion Mejias3.   

Abstract

BACKGROUND: Mechanisms that facilitate early infection and inflammation in cystic fibrosis (CF) are unclear. We previously demonstrated that children with CF and parental-reported secondhand smoke exposure (SHSe) have increased susceptibility to bacterial infections. SHSe hinders arachidonic acid (AA) metabolites that mediate immune function in patients without CF, and may influence CF immune dysfunction. We aimed to define SHSe's impact on inflammation mediators and infection in children with CF.
METHODS: Seventy-seven children with CF <10 years of age (35 infants <1 year; 42 children 1-10 years) were enrolled and hair nicotine concentrations measured as an objective surrogate of SHSe. AA signalling by serum and macrophage lipidomics, inflammation using blood transcriptional profiles and in vitro macrophage responses to bacterial infection after SHSe were assessed.
RESULTS: Hair nicotine concentrations were elevated in 63% of patients. Of the AA metabolites measured by plasma lipidomics, prostaglandin D2 (PGD2) concentrations were decreased in children with CF exposed to SHSe, and associated with more frequent hospitalisations (p=0.007) and worsened weight z scores (p=0.008). Children with CF exposed to SHSe demonstrated decreased expression of the prostaglandin genes PTGES3 and PTGR2 and overexpression of inflammatory pathways. These findings were confirmed using an in vitro model, where SHSe was associated with a dose-dependent decrease in PGD2 and increased methicillin-resistant Staphylococcus aureus survival in human CF macrophages.
CONCLUSIONS: Infants and young children with CF and SHSe have altered AA metabolism and dysregulated inflammatory gene expression resulting in impaired bacterial clearance. Our findings identified potential therapeutic targets to halt early disease progression associated with SHSe in the young population with CF. © Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cystic fibrosis; macrophage biology; paediatric lung disaese; tobacco and the lung

Mesh:

Substances:

Year:  2019        PMID: 30661024     DOI: 10.1136/thoraxjnl-2018-211845

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  9 in total

1.  Whole-blood transcriptomic responses to lumacaftor/ivacaftor therapy in cystic fibrosis.

Authors:  Benjamin T Kopp; James Fitch; Lisa Jaramillo; Chandra L Shrestha; Frank Robledo-Avila; Shuzhong Zhang; Sabrina Palacios; Fred Woodley; Don Hayes; Santiago Partida-Sanchez; Octavio Ramilo; Peter White; Asuncion Mejias
Journal:  J Cyst Fibros       Date:  2019-08-29       Impact factor: 5.482

2.  Age and environmental exposures influence the fecal bacteriome of young children with cystic fibrosis.

Authors:  Brett R Loman; Chandra L Shrestha; Rohan Thompson; Judith A Groner; Asuncion Mejias; Kathryn L Ruoff; George A O'Toole; Michael T Bailey; Benjamin T Kopp
Journal:  Pediatr Pulmonol       Date:  2020-04-10

3.  Sweat metabolomics before and after intravenous antibiotics for pulmonary exacerbation in people with cystic fibrosis.

Authors:  Frederick W Woodley; Emrah Gecili; Rhonda D Szczesniak; Chandra L Shrestha; Christopher J Nemastil; Benjamin T Kopp; Don Hayes
Journal:  Respir Med       Date:  2021-11-23       Impact factor: 3.415

Review 4.  Socioeconomic determinants of respiratory health in patients with cystic fibrosis: implications for treatment strategies.

Authors:  Gabriela R Oates; Michael S Schechter
Journal:  Expert Rev Respir Med       Date:  2022-06-23       Impact factor: 4.300

5.  Tobacco smoke exposure in pediatric cystic fibrosis: A qualitative study of clinician and caregiver perspectives on smoking cessation.

Authors:  Gabriela R Oates; William T Harris; Hector H Gutierrez; Cathy Mims; Sarah B Rutland; Corilyn Ott; Soumya J Niranjan; Isabel C Scarinci; Susan C Walley
Journal:  Pediatr Pulmonol       Date:  2020-06-08

Review 6.  Influence of Second-Hand Smoke and Prenatal Tobacco Smoke Exposure on Biomarkers, Genetics and Physiological Processes in Children-An Overview in Research Insights of the Last Few Years.

Authors:  Markus Braun; Doris Klingelhöfer; Gerhard M Oremek; David Quarcoo; David A Groneberg
Journal:  Int J Environ Res Public Health       Date:  2020-05-05       Impact factor: 3.390

Review 7.  Influences of environmental exposures on individuals living with cystic fibrosis.

Authors:  Rhonda Szczesniak; Jessica L Rice; Cole Brokamp; Patrick Ryan; Teresa Pestian; Yizhao Ni; Eleni-Rosalina Andrinopoulou; Ruth H Keogh; Emrah Gecili; Rui Huang; John P Clancy; Joseph M Collaco
Journal:  Expert Rev Respir Med       Date:  2020-04-26       Impact factor: 3.772

8.  Metabolomics profiling of tobacco exposure in children with cystic fibrosis.

Authors:  Benjamin L Wisniewski; Chandra L Shrestha; Shuzhong Zhang; Rohan Thompson; Myron Gross; Judith A Groner; Karan Uppal; Octavio Ramilo; Asuncion Mejias; Benjamin T Kopp
Journal:  J Cyst Fibros       Date:  2020-05-30       Impact factor: 5.482

Review 9.  Quantification of Phenotypic Variability of Lung Disease in Children with Cystic Fibrosis.

Authors:  Mirjam Stahl; Eva Steinke; Marcus A Mall
Journal:  Genes (Basel)       Date:  2021-05-25       Impact factor: 4.096

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.